Last reviewed · How we verify
Galactomannan
Galactomannan is a Small molecule drug developed by Bioxytran Inc.. It is currently in Phase 3 development.
Galactomannan is a polysaccharide composed of a mannose backbone with galactose side groups, specifically a (1-4)-linked beta-D-mannopyranose backbone with branchpoints from their 6-positions linked to alpha-D-galactose. Galactomannan is a Galectin-1 inhibitor, classified as an INHIBITOR drug modality, and has been studied for its potential in detecting respiratory fungal infections, such as aspergillosis, through non-invasive methods like exhaled breath condensate analysis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Galactomannan |
|---|---|
| Sponsor | Bioxytran Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics (NA)
- Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia
- Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (PHASE2)
- Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients (NA)
- Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial (NA)
- Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients
- Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
- Novel Biomarkers for Invasive Aspergillosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Galactomannan CI brief — competitive landscape report
- Galactomannan updates RSS · CI watch RSS
- Bioxytran Inc. portfolio CI
Frequently asked questions about Galactomannan
What is Galactomannan?
Who makes Galactomannan?
What development phase is Galactomannan in?
Related
- Manufacturer: Bioxytran Inc. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing